PRESS & MEDIA

Stay Informed with the Latest Updates

Sanare Bioscience participates in interviews, expert briefings, and media conversations to support education and awareness around cannabinoid intoxication and CHS. Our leadership contributes perspectives on emerging clinical needs, toxicology insights, and community engagement efforts.

Stay tuned for upcoming publications, video appearances, and public-health commentary.

We provide innovative solutions that work
to bridge gaps in the drug development business. 

Cerebro-1 is an investigational product candidate currently in early-stage development. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). No safety or efficacy has been established. All information on this website is for educational and research-oriented purposes only and is not medical advice.

© 2024 Sanare Bioscience. All rights reserved.

We provide innovative solutions that work
to bridge gaps in the drug development business. 

Cerebro-1 is an investigational product candidate currently in early-stage development. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). No safety or efficacy has been established. All information on this website is for educational and research-oriented purposes only and is not medical advice.

© 2024 Sanare Bioscience. All rights reserved.

We provide innovative solutions that work
to bridge gaps in the drug development business. 

Cerebro-1 is an investigational product candidate currently in early-stage development. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). No safety or efficacy has been established. All information on this website is for educational and research-oriented purposes only and is not medical advice.

© 2024 Sanare Bioscience. All rights reserved.